Global Cell Therapy for Solid Tumor Market Growth (Status and Outlook) 2026-2032
The global Cell Therapy for Solid Tumor market size is predicted to grow from US$ 1971 million in 2025 to US$ 7851 million in 2032; it is expected to grow at a CAGR of 20.9% from 2026 to 2032.
Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.
Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.
The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.
Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from ?whether it works? to ?which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.? Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.
LPI (LP Information)' newest research report, the ?Cell Therapy for Solid Tumor Industry Forecast? looks at past sales and reviews total world Cell Therapy for Solid Tumor sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Therapy for Solid Tumor sales for 2026 through 2032. With Cell Therapy for Solid Tumor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Therapy for Solid Tumor industry.
This Insight Report provides a comprehensive analysis of the global Cell Therapy for Solid Tumor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Therapy for Solid Tumor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cell Therapy for Solid Tumor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Therapy for Solid Tumor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Therapy for Solid Tumor.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Therapy for Solid Tumor market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market.The average gross profit margin of this product is 90%.
Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.
The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.
Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from ?whether it works? to ?which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.? Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.
LPI (LP Information)' newest research report, the ?Cell Therapy for Solid Tumor Industry Forecast? looks at past sales and reviews total world Cell Therapy for Solid Tumor sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Therapy for Solid Tumor sales for 2026 through 2032. With Cell Therapy for Solid Tumor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Therapy for Solid Tumor industry.
This Insight Report provides a comprehensive analysis of the global Cell Therapy for Solid Tumor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Therapy for Solid Tumor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cell Therapy for Solid Tumor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Therapy for Solid Tumor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Therapy for Solid Tumor.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Therapy for Solid Tumor market by product type, application, key players and key regions and countries.
Segmentation by Type:
- CAR-T Therapy
- TCR-T Therapy
- TIL Therapy
- CAR-NK Therapy
- Tumor-Infiltrating NK Or T Cells
- Other
- Autologous Therapy
- Allogeneic Therapy
- Gene-Edited Therapy
- Armored Cell Therapy
- Combination Therapy
- Other
- Melanoma Products
- Gastrointestinal Tumor Products
- Liver Cancer Products
- Lung Cancer Products
- Gynecologic Tumor Products
- Other
- Melanoma
- Lung Cancer
- Liver Cancer
- Gastric And Colorectal Cancer
- Ovarian Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Iovance Biotherapeutics
- Adaptimmune
- Immatics
- CARSgen Therapeutics
- JW Therapeutics
- Legend Biotech
- Gracell Biotechnologies
- Fosun Kite
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cell Therapy for Solid Tumor Market Size (2021-2032)
2.1.2 Cell Therapy for Solid Tumor Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Cell Therapy for Solid Tumor by Country/Region (2021, 2025 & 2032)
2.2 Cell Therapy for Solid Tumor Segment by Type
2.2.1 CAR-T Therapy
2.2.2 TCR-T Therapy
2.2.3 TIL Therapy
2.2.4 CAR-NK Therapy
2.2.5 Tumor-Infiltrating NK Or T Cells
2.2.6 Other
2.2.7 Cell Therapy for Solid Tumor Market Size by Type
2.2.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
2.3 Cell Therapy for Solid Tumor Segment by Cell Source
2.3.1 Autologous Therapy
2.3.2 Allogeneic Therapy
2.3.3 Gene-Edited Therapy
2.3.4 Armored Cell Therapy
2.3.5 Combination Therapy
2.3.6 Other
2.3.7 Cell Therapy for Solid Tumor Market Size by Cell Source
2.3.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Cell Source (2021 VS 2025 VS 2032)
2.3.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2026)
2.4 Cell Therapy for Solid Tumor Segment by Indication
2.4.1 Melanoma Products
2.4.2 Gastrointestinal Tumor Products
2.4.3 Liver Cancer Products
2.4.4 Lung Cancer Products
2.4.5 Gynecologic Tumor Products
2.4.6 Other
2.4.7 Cell Therapy for Solid Tumor Market Size by Indication
2.4.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Indication (2021 VS 2025 VS 2032)
2.4.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2026)
2.5 Cell Therapy for Solid Tumor Segment by Application
2.5.1 Melanoma
2.5.2 Lung Cancer
2.5.3 Liver Cancer
2.5.4 Gastric And Colorectal Cancer
2.5.5 Ovarian Cancer
2.5.6 Other
2.5.7 Cell Therapy for Solid Tumor Market Size by Application
2.5.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
3 CELL THERAPY FOR SOLID TUMOR MARKET SIZE BY PLAYER
3.1 Cell Therapy for Solid Tumor Market Size Market Share by Player
3.1.1 Global Cell Therapy for Solid Tumor Revenue by Player (2021-2026)
3.1.2 Global Cell Therapy for Solid Tumor Revenue Market Share by Player (2021-2026)
3.2 Global Cell Therapy for Solid Tumor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CELL THERAPY FOR SOLID TUMOR BY REGION
4.1 Cell Therapy for Solid Tumor Market Size by Region (2021-2026)
4.2 Global Cell Therapy for Solid Tumor Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
4.4 APAC Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
4.5 Europe Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
4.6 Middle East & Africa Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Cell Therapy for Solid Tumor Market Size by Country (2021-2026)
5.2 Americas Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
5.3 Americas Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cell Therapy for Solid Tumor Market Size by Region (2021-2026)
6.2 APAC Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
6.3 APAC Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Cell Therapy for Solid Tumor Market Size by Country (2021-2026)
7.2 Europe Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
7.3 Europe Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cell Therapy for Solid Tumor by Region (2021-2026)
8.2 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
8.3 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CELL THERAPY FOR SOLID TUMOR MARKET FORECAST
10.1 Global Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.1.1 Global Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.1.2 Americas Cell Therapy for Solid Tumor Forecast
10.1.3 APAC Cell Therapy for Solid Tumor Forecast
10.1.4 Europe Cell Therapy for Solid Tumor Forecast
10.1.5 Middle East & Africa Cell Therapy for Solid Tumor Forecast
10.2 Americas Cell Therapy for Solid Tumor Forecast by Country (2027-2032)
10.2.1 United States Market Cell Therapy for Solid Tumor Forecast
10.2.2 Canada Market Cell Therapy for Solid Tumor Forecast
10.2.3 Mexico Market Cell Therapy for Solid Tumor Forecast
10.2.4 Brazil Market Cell Therapy for Solid Tumor Forecast
10.3 APAC Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.3.1 China Cell Therapy for Solid Tumor Market Forecast
10.3.2 Japan Market Cell Therapy for Solid Tumor Forecast
10.3.3 Korea Market Cell Therapy for Solid Tumor Forecast
10.3.4 Southeast Asia Market Cell Therapy for Solid Tumor Forecast
10.3.5 India Market Cell Therapy for Solid Tumor Forecast
10.3.6 Australia Market Cell Therapy for Solid Tumor Forecast
10.4 Europe Cell Therapy for Solid Tumor Forecast by Country (2027-2032)
10.4.1 Germany Market Cell Therapy for Solid Tumor Forecast
10.4.2 France Market Cell Therapy for Solid Tumor Forecast
10.4.3 UK Market Cell Therapy for Solid Tumor Forecast
10.4.4 Italy Market Cell Therapy for Solid Tumor Forecast
10.4.5 Russia Market Cell Therapy for Solid Tumor Forecast
10.5 Middle East & Africa Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.5.1 Egypt Market Cell Therapy for Solid Tumor Forecast
10.5.2 South Africa Market Cell Therapy for Solid Tumor Forecast
10.5.3 Israel Market Cell Therapy for Solid Tumor Forecast
10.5.4 Turkey Market Cell Therapy for Solid Tumor Forecast
10.6 Global Cell Therapy for Solid Tumor Forecast by Type (2027-2032)
10.7 Global Cell Therapy for Solid Tumor Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Cell Therapy for Solid Tumor Forecast
11 KEY PLAYERS ANALYSIS
11.1 Iovance Biotherapeutics
11.1.1 Iovance Biotherapeutics Company Information
11.1.2 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product Offered
11.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Iovance Biotherapeutics Main Business Overview
11.1.5 Iovance Biotherapeutics Latest Developments
11.2 Adaptimmune
11.2.1 Adaptimmune Company Information
11.2.2 Adaptimmune Cell Therapy for Solid Tumor Product Offered
11.2.3 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Adaptimmune Main Business Overview
11.2.5 Adaptimmune Latest Developments
11.3 Immatics
11.3.1 Immatics Company Information
11.3.2 Immatics Cell Therapy for Solid Tumor Product Offered
11.3.3 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Immatics Main Business Overview
11.3.5 Immatics Latest Developments
11.4 CARSgen Therapeutics
11.4.1 CARSgen Therapeutics Company Information
11.4.2 CARSgen Therapeutics Cell Therapy for Solid Tumor Product Offered
11.4.3 CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CARSgen Therapeutics Main Business Overview
11.4.5 CARSgen Therapeutics Latest Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Information
11.5.2 JW Therapeutics Cell Therapy for Solid Tumor Product Offered
11.5.3 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 JW Therapeutics Main Business Overview
11.5.5 JW Therapeutics Latest Developments
11.6 Legend Biotech
11.6.1 Legend Biotech Company Information
11.6.2 Legend Biotech Cell Therapy for Solid Tumor Product Offered
11.6.3 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Legend Biotech Main Business Overview
11.6.5 Legend Biotech Latest Developments
11.7 Gracell Biotechnologies
11.7.1 Gracell Biotechnologies Company Information
11.7.2 Gracell Biotechnologies Cell Therapy for Solid Tumor Product Offered
11.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Gracell Biotechnologies Main Business Overview
11.7.5 Gracell Biotechnologies Latest Developments
11.8 Fosun Kite
11.8.1 Fosun Kite Company Information
11.8.2 Fosun Kite Cell Therapy for Solid Tumor Product Offered
11.8.3 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Fosun Kite Main Business Overview
11.8.5 Fosun Kite Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cell Therapy for Solid Tumor Market Size (2021-2032)
2.1.2 Cell Therapy for Solid Tumor Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Cell Therapy for Solid Tumor by Country/Region (2021, 2025 & 2032)
2.2 Cell Therapy for Solid Tumor Segment by Type
2.2.1 CAR-T Therapy
2.2.2 TCR-T Therapy
2.2.3 TIL Therapy
2.2.4 CAR-NK Therapy
2.2.5 Tumor-Infiltrating NK Or T Cells
2.2.6 Other
2.2.7 Cell Therapy for Solid Tumor Market Size by Type
2.2.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
2.3 Cell Therapy for Solid Tumor Segment by Cell Source
2.3.1 Autologous Therapy
2.3.2 Allogeneic Therapy
2.3.3 Gene-Edited Therapy
2.3.4 Armored Cell Therapy
2.3.5 Combination Therapy
2.3.6 Other
2.3.7 Cell Therapy for Solid Tumor Market Size by Cell Source
2.3.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Cell Source (2021 VS 2025 VS 2032)
2.3.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2026)
2.4 Cell Therapy for Solid Tumor Segment by Indication
2.4.1 Melanoma Products
2.4.2 Gastrointestinal Tumor Products
2.4.3 Liver Cancer Products
2.4.4 Lung Cancer Products
2.4.5 Gynecologic Tumor Products
2.4.6 Other
2.4.7 Cell Therapy for Solid Tumor Market Size by Indication
2.4.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Indication (2021 VS 2025 VS 2032)
2.4.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2026)
2.5 Cell Therapy for Solid Tumor Segment by Application
2.5.1 Melanoma
2.5.2 Lung Cancer
2.5.3 Liver Cancer
2.5.4 Gastric And Colorectal Cancer
2.5.5 Ovarian Cancer
2.5.6 Other
2.5.7 Cell Therapy for Solid Tumor Market Size by Application
2.5.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
3 CELL THERAPY FOR SOLID TUMOR MARKET SIZE BY PLAYER
3.1 Cell Therapy for Solid Tumor Market Size Market Share by Player
3.1.1 Global Cell Therapy for Solid Tumor Revenue by Player (2021-2026)
3.1.2 Global Cell Therapy for Solid Tumor Revenue Market Share by Player (2021-2026)
3.2 Global Cell Therapy for Solid Tumor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CELL THERAPY FOR SOLID TUMOR BY REGION
4.1 Cell Therapy for Solid Tumor Market Size by Region (2021-2026)
4.2 Global Cell Therapy for Solid Tumor Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
4.4 APAC Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
4.5 Europe Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
4.6 Middle East & Africa Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Cell Therapy for Solid Tumor Market Size by Country (2021-2026)
5.2 Americas Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
5.3 Americas Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cell Therapy for Solid Tumor Market Size by Region (2021-2026)
6.2 APAC Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
6.3 APAC Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Cell Therapy for Solid Tumor Market Size by Country (2021-2026)
7.2 Europe Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
7.3 Europe Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cell Therapy for Solid Tumor by Region (2021-2026)
8.2 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
8.3 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CELL THERAPY FOR SOLID TUMOR MARKET FORECAST
10.1 Global Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.1.1 Global Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.1.2 Americas Cell Therapy for Solid Tumor Forecast
10.1.3 APAC Cell Therapy for Solid Tumor Forecast
10.1.4 Europe Cell Therapy for Solid Tumor Forecast
10.1.5 Middle East & Africa Cell Therapy for Solid Tumor Forecast
10.2 Americas Cell Therapy for Solid Tumor Forecast by Country (2027-2032)
10.2.1 United States Market Cell Therapy for Solid Tumor Forecast
10.2.2 Canada Market Cell Therapy for Solid Tumor Forecast
10.2.3 Mexico Market Cell Therapy for Solid Tumor Forecast
10.2.4 Brazil Market Cell Therapy for Solid Tumor Forecast
10.3 APAC Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.3.1 China Cell Therapy for Solid Tumor Market Forecast
10.3.2 Japan Market Cell Therapy for Solid Tumor Forecast
10.3.3 Korea Market Cell Therapy for Solid Tumor Forecast
10.3.4 Southeast Asia Market Cell Therapy for Solid Tumor Forecast
10.3.5 India Market Cell Therapy for Solid Tumor Forecast
10.3.6 Australia Market Cell Therapy for Solid Tumor Forecast
10.4 Europe Cell Therapy for Solid Tumor Forecast by Country (2027-2032)
10.4.1 Germany Market Cell Therapy for Solid Tumor Forecast
10.4.2 France Market Cell Therapy for Solid Tumor Forecast
10.4.3 UK Market Cell Therapy for Solid Tumor Forecast
10.4.4 Italy Market Cell Therapy for Solid Tumor Forecast
10.4.5 Russia Market Cell Therapy for Solid Tumor Forecast
10.5 Middle East & Africa Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
10.5.1 Egypt Market Cell Therapy for Solid Tumor Forecast
10.5.2 South Africa Market Cell Therapy for Solid Tumor Forecast
10.5.3 Israel Market Cell Therapy for Solid Tumor Forecast
10.5.4 Turkey Market Cell Therapy for Solid Tumor Forecast
10.6 Global Cell Therapy for Solid Tumor Forecast by Type (2027-2032)
10.7 Global Cell Therapy for Solid Tumor Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Cell Therapy for Solid Tumor Forecast
11 KEY PLAYERS ANALYSIS
11.1 Iovance Biotherapeutics
11.1.1 Iovance Biotherapeutics Company Information
11.1.2 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product Offered
11.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Iovance Biotherapeutics Main Business Overview
11.1.5 Iovance Biotherapeutics Latest Developments
11.2 Adaptimmune
11.2.1 Adaptimmune Company Information
11.2.2 Adaptimmune Cell Therapy for Solid Tumor Product Offered
11.2.3 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Adaptimmune Main Business Overview
11.2.5 Adaptimmune Latest Developments
11.3 Immatics
11.3.1 Immatics Company Information
11.3.2 Immatics Cell Therapy for Solid Tumor Product Offered
11.3.3 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Immatics Main Business Overview
11.3.5 Immatics Latest Developments
11.4 CARSgen Therapeutics
11.4.1 CARSgen Therapeutics Company Information
11.4.2 CARSgen Therapeutics Cell Therapy for Solid Tumor Product Offered
11.4.3 CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CARSgen Therapeutics Main Business Overview
11.4.5 CARSgen Therapeutics Latest Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Information
11.5.2 JW Therapeutics Cell Therapy for Solid Tumor Product Offered
11.5.3 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 JW Therapeutics Main Business Overview
11.5.5 JW Therapeutics Latest Developments
11.6 Legend Biotech
11.6.1 Legend Biotech Company Information
11.6.2 Legend Biotech Cell Therapy for Solid Tumor Product Offered
11.6.3 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Legend Biotech Main Business Overview
11.6.5 Legend Biotech Latest Developments
11.7 Gracell Biotechnologies
11.7.1 Gracell Biotechnologies Company Information
11.7.2 Gracell Biotechnologies Cell Therapy for Solid Tumor Product Offered
11.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Gracell Biotechnologies Main Business Overview
11.7.5 Gracell Biotechnologies Latest Developments
11.8 Fosun Kite
11.8.1 Fosun Kite Company Information
11.8.2 Fosun Kite Cell Therapy for Solid Tumor Product Offered
11.8.3 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Fosun Kite Main Business Overview
11.8.5 Fosun Kite Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Cell Therapy for Solid Tumor Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Cell Therapy for Solid Tumor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of CAR-T Therapy
Table 4. Major Players of TCR-T Therapy
Table 5. Major Players of TIL Therapy
Table 6. Major Players of CAR-NK Therapy
Table 7. Major Players of Tumor-Infiltrating NK Or T Cells
Table 8. Major Players of Other
Table 9. Cell Therapy for Solid Tumor Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Autologous Therapy
Table 13. Major Players of Allogeneic Therapy
Table 14. Major Players of Gene-Edited Therapy
Table 15. Major Players of Armored Cell Therapy
Table 16. Major Players of Combination Therapy
Table 17. Major Players of Other
Table 18. Cell Therapy for Solid Tumor Market Size CAGR by Cell Source (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Cell Therapy for Solid Tumor Market Size by Cell Source (2021-2026) & ($ millions)
Table 20. Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2026)
Table 21. Major Players of Melanoma Products
Table 22. Major Players of Gastrointestinal Tumor Products
Table 23. Major Players of Liver Cancer Products
Table 24. Major Players of Lung Cancer Products
Table 25. Major Players of Gynecologic Tumor Products
Table 26. Major Players of Other
Table 27. Cell Therapy for Solid Tumor Market Size CAGR by Indication (2021 VS 2025 VS 2032) & ($ millions)
Table 28. Global Cell Therapy for Solid Tumor Market Size by Indication (2021-2026) & ($ millions)
Table 29. Global Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2026)
Table 30. Cell Therapy for Solid Tumor Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 31. Global Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 32. Global Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Table 33. Global Cell Therapy for Solid Tumor Revenue by Player (2021-2026) & ($ millions)
Table 34. Global Cell Therapy for Solid Tumor Revenue Market Share by Player (2021-2026)
Table 35. Cell Therapy for Solid Tumor Key Players Head office and Products Offered
Table 36. Cell Therapy for Solid Tumor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Mergers & Acquisitions, Expansion
Table 39. Global Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & ($ millions)
Table 40. Global Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Table 41. Global Cell Therapy for Solid Tumor Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Cell Therapy for Solid Tumor Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Cell Therapy for Solid Tumor Market Size by Country (2021-2026) & ($ millions)
Table 44. Americas Cell Therapy for Solid Tumor Market Size Market Share by Country (2021-2026)
Table 45. Americas Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 46. Americas Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Table 47. Americas Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 48. Americas Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Table 49. APAC Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & ($ millions)
Table 50. APAC Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Table 51. APAC Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 52. APAC Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 53. Europe Cell Therapy for Solid Tumor Market Size by Country (2021-2026) & ($ millions)
Table 54. Europe Cell Therapy for Solid Tumor Market Size Market Share by Country (2021-2026)
Table 55. Europe Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 56. Europe Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 57. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & ($ millions)
Table 58. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 59. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 60. Key Market Drivers & Growth Opportunities of Cell Therapy for Solid Tumor
Table 61. Key Market Challenges & Risks of Cell Therapy for Solid Tumor
Table 62. Key Industry Trends of Cell Therapy for Solid Tumor
Table 63. Global Cell Therapy for Solid Tumor Market Size Forecast by Region (2027-2032) & ($ millions)
Table 64. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Region (2027-2032)
Table 65. Global Cell Therapy for Solid Tumor Market Size Forecast by Type (2027-2032) & ($ millions)
Table 66. Global Cell Therapy for Solid Tumor Market Size Forecast by Application (2027-2032) & ($ millions)
Table 67. Iovance Biotherapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 68. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product Offered
Table 69. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Iovance Biotherapeutics Main Business
Table 71. Iovance Biotherapeutics Latest Developments
Table 72. Adaptimmune Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 73. Adaptimmune Cell Therapy for Solid Tumor Product Offered
Table 74. Adaptimmune Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Adaptimmune Main Business
Table 76. Adaptimmune Latest Developments
Table 77. Immatics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 78. Immatics Cell Therapy for Solid Tumor Product Offered
Table 79. Immatics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Immatics Main Business
Table 81. Immatics Latest Developments
Table 82. CARSgen Therapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 83. CARSgen Therapeutics Cell Therapy for Solid Tumor Product Offered
Table 84. CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. CARSgen Therapeutics Main Business
Table 86. CARSgen Therapeutics Latest Developments
Table 87. JW Therapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 88. JW Therapeutics Cell Therapy for Solid Tumor Product Offered
Table 89. JW Therapeutics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. JW Therapeutics Main Business
Table 91. JW Therapeutics Latest Developments
Table 92. Legend Biotech Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 93. Legend Biotech Cell Therapy for Solid Tumor Product Offered
Table 94. Legend Biotech Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Legend Biotech Main Business
Table 96. Legend Biotech Latest Developments
Table 97. Gracell Biotechnologies Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 98. Gracell Biotechnologies Cell Therapy for Solid Tumor Product Offered
Table 99. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Gracell Biotechnologies Main Business
Table 101. Gracell Biotechnologies Latest Developments
Table 102. Fosun Kite Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 103. Fosun Kite Cell Therapy for Solid Tumor Product Offered
Table 104. Fosun Kite Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Fosun Kite Main Business
Table 106. Fosun Kite Latest Developments
Table 1. Cell Therapy for Solid Tumor Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Cell Therapy for Solid Tumor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of CAR-T Therapy
Table 4. Major Players of TCR-T Therapy
Table 5. Major Players of TIL Therapy
Table 6. Major Players of CAR-NK Therapy
Table 7. Major Players of Tumor-Infiltrating NK Or T Cells
Table 8. Major Players of Other
Table 9. Cell Therapy for Solid Tumor Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Autologous Therapy
Table 13. Major Players of Allogeneic Therapy
Table 14. Major Players of Gene-Edited Therapy
Table 15. Major Players of Armored Cell Therapy
Table 16. Major Players of Combination Therapy
Table 17. Major Players of Other
Table 18. Cell Therapy for Solid Tumor Market Size CAGR by Cell Source (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Cell Therapy for Solid Tumor Market Size by Cell Source (2021-2026) & ($ millions)
Table 20. Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2026)
Table 21. Major Players of Melanoma Products
Table 22. Major Players of Gastrointestinal Tumor Products
Table 23. Major Players of Liver Cancer Products
Table 24. Major Players of Lung Cancer Products
Table 25. Major Players of Gynecologic Tumor Products
Table 26. Major Players of Other
Table 27. Cell Therapy for Solid Tumor Market Size CAGR by Indication (2021 VS 2025 VS 2032) & ($ millions)
Table 28. Global Cell Therapy for Solid Tumor Market Size by Indication (2021-2026) & ($ millions)
Table 29. Global Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2026)
Table 30. Cell Therapy for Solid Tumor Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 31. Global Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 32. Global Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Table 33. Global Cell Therapy for Solid Tumor Revenue by Player (2021-2026) & ($ millions)
Table 34. Global Cell Therapy for Solid Tumor Revenue Market Share by Player (2021-2026)
Table 35. Cell Therapy for Solid Tumor Key Players Head office and Products Offered
Table 36. Cell Therapy for Solid Tumor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Mergers & Acquisitions, Expansion
Table 39. Global Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & ($ millions)
Table 40. Global Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Table 41. Global Cell Therapy for Solid Tumor Revenue by Country/Region (2021-2026) & ($ millions)
Table 42. Global Cell Therapy for Solid Tumor Revenue Market Share by Country/Region (2021-2026)
Table 43. Americas Cell Therapy for Solid Tumor Market Size by Country (2021-2026) & ($ millions)
Table 44. Americas Cell Therapy for Solid Tumor Market Size Market Share by Country (2021-2026)
Table 45. Americas Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 46. Americas Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Table 47. Americas Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 48. Americas Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Table 49. APAC Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & ($ millions)
Table 50. APAC Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Table 51. APAC Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 52. APAC Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 53. Europe Cell Therapy for Solid Tumor Market Size by Country (2021-2026) & ($ millions)
Table 54. Europe Cell Therapy for Solid Tumor Market Size Market Share by Country (2021-2026)
Table 55. Europe Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 56. Europe Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 57. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & ($ millions)
Table 58. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & ($ millions)
Table 59. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & ($ millions)
Table 60. Key Market Drivers & Growth Opportunities of Cell Therapy for Solid Tumor
Table 61. Key Market Challenges & Risks of Cell Therapy for Solid Tumor
Table 62. Key Industry Trends of Cell Therapy for Solid Tumor
Table 63. Global Cell Therapy for Solid Tumor Market Size Forecast by Region (2027-2032) & ($ millions)
Table 64. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Region (2027-2032)
Table 65. Global Cell Therapy for Solid Tumor Market Size Forecast by Type (2027-2032) & ($ millions)
Table 66. Global Cell Therapy for Solid Tumor Market Size Forecast by Application (2027-2032) & ($ millions)
Table 67. Iovance Biotherapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 68. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product Offered
Table 69. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Iovance Biotherapeutics Main Business
Table 71. Iovance Biotherapeutics Latest Developments
Table 72. Adaptimmune Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 73. Adaptimmune Cell Therapy for Solid Tumor Product Offered
Table 74. Adaptimmune Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Adaptimmune Main Business
Table 76. Adaptimmune Latest Developments
Table 77. Immatics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 78. Immatics Cell Therapy for Solid Tumor Product Offered
Table 79. Immatics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Immatics Main Business
Table 81. Immatics Latest Developments
Table 82. CARSgen Therapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 83. CARSgen Therapeutics Cell Therapy for Solid Tumor Product Offered
Table 84. CARSgen Therapeutics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. CARSgen Therapeutics Main Business
Table 86. CARSgen Therapeutics Latest Developments
Table 87. JW Therapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 88. JW Therapeutics Cell Therapy for Solid Tumor Product Offered
Table 89. JW Therapeutics Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. JW Therapeutics Main Business
Table 91. JW Therapeutics Latest Developments
Table 92. Legend Biotech Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 93. Legend Biotech Cell Therapy for Solid Tumor Product Offered
Table 94. Legend Biotech Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Legend Biotech Main Business
Table 96. Legend Biotech Latest Developments
Table 97. Gracell Biotechnologies Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 98. Gracell Biotechnologies Cell Therapy for Solid Tumor Product Offered
Table 99. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Gracell Biotechnologies Main Business
Table 101. Gracell Biotechnologies Latest Developments
Table 102. Fosun Kite Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors
Table 103. Fosun Kite Cell Therapy for Solid Tumor Product Offered
Table 104. Fosun Kite Cell Therapy for Solid Tumor Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Fosun Kite Main Business
Table 106. Fosun Kite Latest Developments
LIST OF FIGURES
Figure 1. Cell Therapy for Solid Tumor Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Cell Therapy for Solid Tumor Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Cell Therapy for Solid Tumor Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Cell Therapy for Solid Tumor Sales Market Share by Country/Region (2025)
Figure 8. Cell Therapy for Solid Tumor Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Cell Therapy for Solid Tumor Market Size Market Share by Type in 2025
Figure 10. Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source in 2025
Figure 11. Global Cell Therapy for Solid Tumor Market Size Market Share by Indication in 2025
Figure 12. Cell Therapy for Solid Tumor in Melanoma
Figure 13. Global Cell Therapy for Solid Tumor Market: Melanoma (2021-2026) & ($ millions)
Figure 14. Cell Therapy for Solid Tumor in Lung Cancer
Figure 15. Global Cell Therapy for Solid Tumor Market: Lung Cancer (2021-2026) & ($ millions)
Figure 16. Cell Therapy for Solid Tumor in Liver Cancer
Figure 17. Global Cell Therapy for Solid Tumor Market: Liver Cancer (2021-2026) & ($ millions)
Figure 18. Cell Therapy for Solid Tumor in Gastric And Colorectal Cancer
Figure 19. Global Cell Therapy for Solid Tumor Market: Gastric And Colorectal Cancer (2021-2026) & ($ millions)
Figure 20. Cell Therapy for Solid Tumor in Ovarian Cancer
Figure 21. Global Cell Therapy for Solid Tumor Market: Ovarian Cancer (2021-2026) & ($ millions)
Figure 22. Cell Therapy for Solid Tumor in Other
Figure 23. Global Cell Therapy for Solid Tumor Market: Other (2021-2026) & ($ millions)
Figure 24. Global Cell Therapy for Solid Tumor Market Size Market Share by Application in 2025
Figure 25. Global Cell Therapy for Solid Tumor Revenue Market Share by Player in 2025
Figure 26. Global Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Figure 27. Americas Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 28. APAC Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 29. Europe Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 30. Middle East & Africa Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 31. Americas Cell Therapy for Solid Tumor Value Market Share by Country in 2025
Figure 32. United States Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 33. Canada Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 34. Mexico Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 35. Brazil Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 36. APAC Cell Therapy for Solid Tumor Market Size Market Share by Region in 2025
Figure 37. APAC Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Figure 38. APAC Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Figure 39. China Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 40. Japan Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 41. South Korea Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 42. Southeast Asia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 43. India Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 44. Australia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 45. Europe Cell Therapy for Solid Tumor Market Size Market Share by Country in 2025
Figure 46. Europe Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Figure 47. Europe Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Figure 48. Germany Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 49. France Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 50. UK Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 51. Italy Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 52. Russia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 53. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Figure 54. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Figure 55. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Figure 56. Egypt Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 57. South Africa Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 58. Israel Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 59. Turkey Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 60. GCC Countries Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 61. Americas Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 62. APAC Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 63. Europe Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 64. Middle East & Africa Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 65. United States Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 66. Canada Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 67. Mexico Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 68. Brazil Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 69. China Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 70. Japan Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 71. Korea Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 72. Southeast Asia Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 73. India Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 74. Australia Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 75. Germany Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 76. France Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 77. UK Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 78. Italy Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 79. Russia Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 80. Egypt Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 81. South Africa Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 82. Israel Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 83. Turkey Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 84. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Type (2027-2032)
Figure 85. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Application (2027-2032)
Figure 86. GCC Countries Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 1. Cell Therapy for Solid Tumor Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Cell Therapy for Solid Tumor Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Cell Therapy for Solid Tumor Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Cell Therapy for Solid Tumor Sales Market Share by Country/Region (2025)
Figure 8. Cell Therapy for Solid Tumor Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Cell Therapy for Solid Tumor Market Size Market Share by Type in 2025
Figure 10. Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source in 2025
Figure 11. Global Cell Therapy for Solid Tumor Market Size Market Share by Indication in 2025
Figure 12. Cell Therapy for Solid Tumor in Melanoma
Figure 13. Global Cell Therapy for Solid Tumor Market: Melanoma (2021-2026) & ($ millions)
Figure 14. Cell Therapy for Solid Tumor in Lung Cancer
Figure 15. Global Cell Therapy for Solid Tumor Market: Lung Cancer (2021-2026) & ($ millions)
Figure 16. Cell Therapy for Solid Tumor in Liver Cancer
Figure 17. Global Cell Therapy for Solid Tumor Market: Liver Cancer (2021-2026) & ($ millions)
Figure 18. Cell Therapy for Solid Tumor in Gastric And Colorectal Cancer
Figure 19. Global Cell Therapy for Solid Tumor Market: Gastric And Colorectal Cancer (2021-2026) & ($ millions)
Figure 20. Cell Therapy for Solid Tumor in Ovarian Cancer
Figure 21. Global Cell Therapy for Solid Tumor Market: Ovarian Cancer (2021-2026) & ($ millions)
Figure 22. Cell Therapy for Solid Tumor in Other
Figure 23. Global Cell Therapy for Solid Tumor Market: Other (2021-2026) & ($ millions)
Figure 24. Global Cell Therapy for Solid Tumor Market Size Market Share by Application in 2025
Figure 25. Global Cell Therapy for Solid Tumor Revenue Market Share by Player in 2025
Figure 26. Global Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Figure 27. Americas Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 28. APAC Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 29. Europe Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 30. Middle East & Africa Cell Therapy for Solid Tumor Market Size 2021-2026 ($ millions)
Figure 31. Americas Cell Therapy for Solid Tumor Value Market Share by Country in 2025
Figure 32. United States Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 33. Canada Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 34. Mexico Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 35. Brazil Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 36. APAC Cell Therapy for Solid Tumor Market Size Market Share by Region in 2025
Figure 37. APAC Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Figure 38. APAC Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Figure 39. China Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 40. Japan Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 41. South Korea Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 42. Southeast Asia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 43. India Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 44. Australia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 45. Europe Cell Therapy for Solid Tumor Market Size Market Share by Country in 2025
Figure 46. Europe Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Figure 47. Europe Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Figure 48. Germany Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 49. France Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 50. UK Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 51. Italy Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 52. Russia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 53. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)
Figure 54. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)
Figure 55. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)
Figure 56. Egypt Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 57. South Africa Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 58. Israel Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 59. Turkey Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 60. GCC Countries Cell Therapy for Solid Tumor Market Size Growth 2021-2026 ($ millions)
Figure 61. Americas Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 62. APAC Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 63. Europe Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 64. Middle East & Africa Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 65. United States Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 66. Canada Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 67. Mexico Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 68. Brazil Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 69. China Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 70. Japan Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 71. Korea Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 72. Southeast Asia Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 73. India Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 74. Australia Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 75. Germany Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 76. France Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 77. UK Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 78. Italy Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 79. Russia Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 80. Egypt Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 81. South Africa Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 82. Israel Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 83. Turkey Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
Figure 84. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Type (2027-2032)
Figure 85. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Application (2027-2032)
Figure 86. GCC Countries Cell Therapy for Solid Tumor Market Size 2027-2032 ($ millions)
